Clinical
RSSArticles
-
Now Is the Time to Change Label on Emergency Contraceptives
The FDA should change the labeling for levonorgestrel-based emergency contraception to reflect evidence-based knowledge that the drug does not act as an abortifacient, according to researchers. The label change is especially important now, as states are banning abortions and sometimes defining it in ways that would prohibit pharmacies from selling emergency contraception under its current FDA labeling. -
Research Shows Benefits of Policies Increasing Access to Postpartum LARC
Medicaid expansion and other policies can make postpartum LARC more affordable. States also can create ways to make LARC affordable through programs in which hospitals can bill separately for intrauterine devices and their insertion. -
More Low-Income Women Used IUDs After Introduction of Low- or No-Cost Options
LARC offers many safety and efficacy benefits. But there remain barriers in cost and the need for in-person clinic visits. The results of recent research show that as the cost is decreased, the percentage of women using IUDs increased. -
Federal Title X Funding Decimated for Many Providers
A shockwave rocked Title X programs on March 30, when the federal government’s latest round of funding left many facilities with huge budget shortfalls. The Biden administration had reversed the gag rule and asked Congress for more Title X funds. Yet, when Title X funding was announced, many programs received the worst cut in their history with the program. -
Is the Canadian Syncope Risk Score Valid?
Researchers found the Canadian Syncope Risk Score accurately predicts which patients are low risk for discharge. However, since it is largely driven by the physician’s final risk classification at ED discharge, the score’s clinical utility is uncertain.
-
Anticoagulation Therapy in Octogenarians with Atrial Fibrillation
In patients age 80 years and older with atrial fibrillation who were not considered for oral anticoagulants because of serious comorbidities, one-quarter of the recommended daily dose of edoxaban was superior to placebo for preventing thromboembolic events.
-
Outcomes of COVID-19-Associated Acute Myocarditis
In a review of COVID-19-associated acute myocarditis, investigators learned it is a rare complication that can occur without concomitant pneumonia, and frequently presents as cardiogenic shock. With supportive therapy, the short-term mortality rate is low.
-
Sodium Restriction in Chronic, Stable Heart Failure Patients
A study of a low-sodium diet for chronic, stable heart failure patients after one year showed no difference in hard clinical outcomes, but the degree of sodium restriction was modest.
-
Oral Anticoagulation Falls Short as Default Treatment Post-TAVR
In patients without an indication for anticoagulation undergoing transcatheter aortic valve replacement, treatment with edoxaban did not significantly affect the incidence of leaflet thrombosis as detected by CT scans.
-
Multiple Sclerosis Disease Burden May Be Underestimated
Prescription drug prices, indirect productivity loss drive care costs significantly higher for these patients compared to others.